Oragenics, Inc. (OGEN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Oragenics, Inc. on January 22, 2026. The report details a material definitive agreement regarding the company's capital raising activities.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a contractual amendment rather than financial performance results.
Material Changes
On January 22, 2026, Oragenics, Inc. entered into an amendment to its At-the-Market Sales Agreement originally signed on October 11, 2024, with Dawson James Securities Inc. The amendment extends the term of the agreement to expire at the earlier of:
- The issuance and sale of all shares available under the agreement; or
- The later of the expiration of the Company's Shelf Registration Statement on Form S-3 or any replacement registration statement filed with the SEC.
All other terms, conditions, and covenants of the original Sales Agreement remain in full force and effect.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future performance, or specific risk factors beyond the standard incorporation by reference of the Sales Agreement and Amendment. The company continues to have the ability to issue and sell shares of common stock depending on market demand through the NYSE American.
Key Facts for Investor Verification
- Verify the current status and expiration date of the Company's Shelf Registration Statement on Form S-3.
- Review the full text of the Amendment to Sales Agreement (Exhibit 1.2) for any nuanced changes to covenants not explicitly detailed in the summary.
- Monitor subsequent filings for actual share issuances and proceeds generated under the extended agreement.
- Confirm the remaining number of shares available for sale under the original October 2024 agreement.